Berit Markevarn
Overview
Explore the profile of Berit Markevarn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Soderlund S, Dahlen T, Sandin F, Olsson-Stromberg U, Creignou M, Dreimane A, et al.
Eur J Haematol
. 2016 Jul;
98(1):57-66.
PMID: 27428357
Objectives: The primary goal in management of chronic phase (CP) chronic myeloid leukaemia (CML) is to prevent disease progression to accelerated phase (AP) or blast crisis (BC). We have evaluated...
12.
Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A, et al.
Br J Haematol
. 2015 Mar;
169(5):683-8.
PMID: 25817799
Given that tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with chronic myeloid leukaemia (CML), we were interested in examining the possible risk of long-term adverse events,...
13.
Christiansson L, Soderlund S, Mangsbo S, Hjorth-Hansen H, Hoglund M, Markevarn B, et al.
Mol Cancer Ther
. 2015 Mar;
14(5):1181-91.
PMID: 25761894
Immune escape mechanisms promote tumor progression and are hurdles of cancer immunotherapy. Removing immunosuppressive cells before treatment can enhance efficacy. Tyrosine kinase inhibitors (TKI) may be of interest to combine...
14.
Hjorth-Hansen H, Stenke L, Soderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, et al.
Eur J Haematol
. 2014 Aug;
94(3):243-50.
PMID: 25082346
We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat...
15.
Richter J, Soderlund S, Lubking A, Dreimane A, Lotfi K, Markevarn B, et al.
J Clin Oncol
. 2014 Jul;
32(25):2821-3.
PMID: 25071107
No abstract available.
16.
Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M, et al.
Blood
. 2013 Jul;
122(7):1284-92.
PMID: 23843494
Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid...
17.
Ejerblad E, Kvasnicka H, Thiele J, Andreasson B, Bjorkholm M, Lofvenberg E, et al.
Hematology
. 2012 Sep;
18(1):8-13.
PMID: 22990042
Objectives: During long term follow-up of a cohort of patients with essential thrombocythemia (ET) and polycythemia vera (PV) a higher than expected incidence of myelofibrosis (MF) was noted. In order...
18.
Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A, et al.
Blood
. 2011 Jun;
118(12):3228-35.
PMID: 21685374
Biologic and clinical observations suggest that combining imatinib with IFN-α may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or...
19.
Bjorkholm M, Derolf A, Hultcrantz M, Kristinsson S, Ekstrand C, Goldin L, et al.
J Clin Oncol
. 2011 May;
29(17):2410-5.
PMID: 21537037
Purpose: Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to develop acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs). Using population-based data...
20.
Wahlin A, Billstrom R, Bjor O, Ahlgren T, Hedenus M, Hoglund M, et al.
Eur J Haematol
. 2009 Apr;
83(2):99-107.
PMID: 19385987
In 1997-2003, a protocol for treatment of acute myeloid leukaemia (AML) (except promyelocytic leukaemia) was activated in four Swedish health care regions covering 50% of the national population. Based on...